PL2498771T3 - Zastosowanie betanecholu do leczenia kserostomii - Google Patents

Zastosowanie betanecholu do leczenia kserostomii

Info

Publication number
PL2498771T3
PL2498771T3 PL10779033T PL10779033T PL2498771T3 PL 2498771 T3 PL2498771 T3 PL 2498771T3 PL 10779033 T PL10779033 T PL 10779033T PL 10779033 T PL10779033 T PL 10779033T PL 2498771 T3 PL2498771 T3 PL 2498771T3
Authority
PL
Poland
Prior art keywords
bethanechol
xerostomia
treatment
Prior art date
Application number
PL10779033T
Other languages
English (en)
Inventor
Nicola Cooper
Julian Clive Gilbert
Robert William Gristwood
Michael Grant Wyllie
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0919822A external-priority patent/GB0919822D0/en
Priority claimed from GBGB1004445.1A external-priority patent/GB201004445D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of PL2498771T3 publication Critical patent/PL2498771T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL10779033T 2009-11-12 2010-11-11 Zastosowanie betanecholu do leczenia kserostomii PL2498771T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0919822A GB0919822D0 (en) 2009-11-12 2009-11-12 The treatment of salivary gland dysfunction
GBGB1004445.1A GB201004445D0 (en) 2010-03-17 2010-03-17 The treatment of salivary gland dysfunction
PCT/GB2010/051887 WO2011058366A1 (en) 2009-11-12 2010-11-11 Use of bethanechol for treatment of xerostomia
EP10779033.9A EP2498771B1 (en) 2009-11-12 2010-11-11 Use of bethanechol for treatment of xerostomia

Publications (1)

Publication Number Publication Date
PL2498771T3 true PL2498771T3 (pl) 2014-03-31

Family

ID=43382322

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10779033T PL2498771T3 (pl) 2009-11-12 2010-11-11 Zastosowanie betanecholu do leczenia kserostomii

Country Status (23)

Country Link
US (3) US9149454B2 (pl)
EP (1) EP2498771B1 (pl)
JP (1) JP5595513B2 (pl)
KR (1) KR20120092152A (pl)
CN (1) CN102711752B (pl)
AU (1) AU2010317747B2 (pl)
BR (1) BR112012011086A2 (pl)
CA (1) CA2780256A1 (pl)
CY (1) CY1114766T1 (pl)
DK (1) DK2498771T3 (pl)
EA (1) EA022040B1 (pl)
ES (1) ES2443847T3 (pl)
HR (1) HRP20140020T1 (pl)
IL (1) IL219613A (pl)
MX (1) MX2012005456A (pl)
NZ (1) NZ599880A (pl)
PL (1) PL2498771T3 (pl)
PT (1) PT2498771E (pl)
RS (1) RS53124B (pl)
SI (1) SI2498771T1 (pl)
SM (1) SMT201400008B (pl)
WO (1) WO2011058366A1 (pl)
ZA (1) ZA201203289B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
GB201107533D0 (en) 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
GB2523989B (en) 2014-01-30 2020-07-29 Insulet Netherlands B V Therapeutic product delivery system and method of pairing
US10737024B2 (en) 2015-02-18 2020-08-11 Insulet Corporation Fluid delivery and infusion devices, and methods of use thereof
JP6472722B2 (ja) * 2015-06-30 2019-02-20 サンスター株式会社 口腔内投与する唾液分泌促進剤
EP3374905A1 (en) 2016-01-13 2018-09-19 Bigfoot Biomedical, Inc. User interface for diabetes management system
CN112933333B (zh) 2016-01-14 2023-03-28 比格福特生物医药公司 调整胰岛素输送速率
EP3515535A1 (en) 2016-09-23 2019-07-31 Insulet Corporation Fluid delivery device with sensor
SG11202006492SA (en) * 2018-02-05 2020-08-28 Cellix Bio Private Ltd Combination of an antimuscarinic or an anticholinergic agent and lipoic acid and uses thereof
USD928199S1 (en) 2018-04-02 2021-08-17 Bigfoot Biomedical, Inc. Medication delivery device with icons
JP7124120B2 (ja) 2018-05-04 2022-08-23 インスレット コーポレイション 制御アルゴリズムベースの薬物送達システムのための安全制約
EP3856285A1 (en) 2018-09-28 2021-08-04 Insulet Corporation Activity mode for artificial pancreas system
EP3864668A1 (en) 2018-10-11 2021-08-18 Insulet Corporation Event detection for drug delivery system
KR20200083370A (ko) * 2018-12-28 2020-07-08 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
US11801344B2 (en) 2019-09-13 2023-10-31 Insulet Corporation Blood glucose rate of change modulation of meal and correction insulin bolus quantity
US11935637B2 (en) 2019-09-27 2024-03-19 Insulet Corporation Onboarding and total daily insulin adaptivity
KR20210044714A (ko) 2019-10-15 2021-04-23 인하대학교 산학협력단 노화기인 타액선 기능손상 회복을 위한 혈소판 풍부 혈장 기반 치료 조성물
WO2021113647A1 (en) 2019-12-06 2021-06-10 Insulet Corporation Techniques and devices providing adaptivity and personalization in diabetes treatment
US11833329B2 (en) 2019-12-20 2023-12-05 Insulet Corporation Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns
US11551802B2 (en) 2020-02-11 2023-01-10 Insulet Corporation Early meal detection and calorie intake detection
US11547800B2 (en) 2020-02-12 2023-01-10 Insulet Corporation User parameter dependent cost function for personalized reduction of hypoglycemia and/or hyperglycemia in a closed loop artificial pancreas system
US11324889B2 (en) 2020-02-14 2022-05-10 Insulet Corporation Compensation for missing readings from a glucose monitor in an automated insulin delivery system
US11607493B2 (en) 2020-04-06 2023-03-21 Insulet Corporation Initial total daily insulin setting for user onboarding
US11684716B2 (en) 2020-07-31 2023-06-27 Insulet Corporation Techniques to reduce risk of occlusions in drug delivery systems
WO2022080529A1 (ko) * 2020-10-15 2022-04-21 경상대학교병원 침분비 저하증 예방 또는 치료용 약학적 조성물 및 건강기능식품
US11904140B2 (en) 2021-03-10 2024-02-20 Insulet Corporation Adaptable asymmetric medicament cost component in a control system for medicament delivery
US11738144B2 (en) 2021-09-27 2023-08-29 Insulet Corporation Techniques enabling adaptation of parameters in aid systems by user input
US11439754B1 (en) 2021-12-01 2022-09-13 Insulet Corporation Optimizing embedded formulations for drug delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102340D0 (sv) 1991-08-13 1991-08-13 Astra Ab Pharmaceutical composition containing carbachol and othercholinergic substances
JP2683783B2 (ja) 1992-07-10 1997-12-03 雪印乳業株式会社 シェーグレン症候群治療剤
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
ZA9610154B (en) 1995-12-12 1997-06-17 Universiteit Van Preporia Mouthwash
GB9618341D0 (en) * 1996-09-03 1996-10-16 Scotia Holdings Plc Method of treatment
CN100379423C (zh) * 1997-02-24 2008-04-09 S.L.A.药业股份公司 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
WO2007092811A2 (en) * 2006-02-07 2007-08-16 Whitehill Oral Technologies, Inc. Sialagogue based oral care products
US20100010031A1 (en) 2007-02-09 2010-01-14 Yum Ii Su Transoral dosage forms comprising sufentanil and naloxone

Also Published As

Publication number Publication date
EP2498771B1 (en) 2013-12-25
IL219613A0 (en) 2012-07-31
SMT201400008B (it) 2014-03-07
EA201270619A1 (ru) 2012-12-28
WO2011058366A1 (en) 2011-05-19
US20160287512A1 (en) 2016-10-06
KR20120092152A (ko) 2012-08-20
CA2780256A1 (en) 2011-05-19
HRP20140020T1 (hr) 2014-02-14
CN102711752B (zh) 2014-06-18
AU2010317747B2 (en) 2013-10-17
AU2010317747A1 (en) 2012-05-31
MX2012005456A (es) 2012-06-19
US20120232137A1 (en) 2012-09-13
JP5595513B2 (ja) 2014-09-24
US9149454B2 (en) 2015-10-06
EA022040B1 (ru) 2015-10-30
SI2498771T1 (sl) 2014-04-30
CN102711752A (zh) 2012-10-03
RS53124B (en) 2014-06-30
ES2443847T3 (es) 2014-02-20
CY1114766T1 (el) 2016-12-14
EP2498771A1 (en) 2012-09-19
IL219613A (en) 2016-12-29
US10137084B2 (en) 2018-11-27
BR112012011086A2 (pt) 2016-07-05
DK2498771T3 (da) 2014-01-27
PT2498771E (pt) 2014-01-30
JP2013510840A (ja) 2013-03-28
US20150366794A1 (en) 2015-12-24
ZA201203289B (en) 2013-09-25
NZ599880A (en) 2014-03-28

Similar Documents

Publication Publication Date Title
IL219613A0 (en) Use of bethanechol for treatment xerostomia
ZA201304280B (en) Treatment of jak2-mediated conditions
PL2652193T3 (pl) Obróbka
GB201000916D0 (en) Treatment of biofilms
GB0919097D0 (en) Treatment of hard surfaces
GB0915515D0 (en) Treatment of vasculoproliferative conditions
GB0902876D0 (en) Novel use of polymers
IL206491A0 (en) Treatment of produce
PT2745837T (pt) Tratamento de glomerulonefrite
IL256026A (en) Treatment methods
GB2482171B (en) Catalyst treatment
HK1160925A1 (zh) 組織蛋白酶 的用途
GB0901456D0 (en) Treatment of psoriasis
ZA201102173B (en) Treatment of water
PL2493496T3 (pl) Zastosowanie GSTP1
GB0900599D0 (en) Treatment
GB201013573D0 (en) Treatment
IL200753A0 (en) Treatment of psoriasis
GB0908101D0 (en) Treatment of stress
EP2403507A4 (en) TREATMENT OF INFECTIONS
GB0913968D0 (en) Treatment
GB0901411D0 (en) Treatment
HK1160777A1 (en) Novel use of neohesperidoside
EP2440238A4 (en) Methods of Treatment
GB201014097D0 (en) Treatment